KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Invested Capital: 2010-2024

Historic Invested Capital for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $1.2 billion.

  • Emergent BioSolutions' Invested Capital rose 5.49% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 5.49%. This contributed to the annual value of $1.2 billion for FY2024, which is 22.07% down from last year.
  • Per Emergent BioSolutions' latest filing, its Invested Capital stood at $1.2 billion for FY2024, which was down 22.07% from $1.5 billion recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Invested Capital registered a high of $2.8 billion during FY2022, and its lowest value of $1.2 billion during FY2024.
  • Over the past 3 years, Emergent BioSolutions' median Invested Capital value was $1.5 billion (recorded in 2023), while the average stood at $1.8 billion.
  • In the last 5 years, Emergent BioSolutions' Invested Capital climbed by 22.26% in 2020 and then plummeted by 45.83% in 2023.
  • Emergent BioSolutions' Invested Capital (Yearly) stood at $2.3 billion in 2020, then grew by 5.34% to $2.5 billion in 2021, then grew by 13.83% to $2.8 billion in 2022, then plummeted by 45.83% to $1.5 billion in 2023, then fell by 22.07% to $1.2 billion in 2024.